Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P135

ECE2006 Poster Presentations Clinical case reports (128 abstracts)

The effects of lanreotide administration vs unilateral adrenalectomy on disease activity in gip-dependent cushing’s syndrome

M Robaczyk , B Krzyzanowska-Swiniarska , G Kulig & K Pilarska


Pomeranian Medical Academy (PAM), Department of Endocrinology, Hypertension and Metabolic Diseases, Szczecin, Poland.


GIP-dependent Cushing’s syndrome (CS) is caused by ectopic expression in adrenal cortex of gastric inhibitory peptide (GIP) receptors coupled to steroidogenesis, which leads to postprandial increases of cortisol (food-dependent CS). In a few cases a transient effect of short-acting octreotide on cortisol levels has been shown, but bilateral adrenalectomy is still thought to be a definitive treatment.

We report on a case of a 45-year old woman with bilateral macronodular adrenal hyperplasia and clinically apparent CS, chronically treated for several years with aminogluthetimide (A). After we had observed that pre-treatment with octreotide s.c. prevents an increase in cortisol levels during OGTT, we administered a single dose (30 mg i.m.) of long-acting lanreotide (Ipsen Biotech) after 4 weeks’ withdrawal of A. Plasma pre- and postprandial levels (90 min.) of intact GIP and cortisol (6-point profile), as well as blood glucose and urinary free cortisol (UFC) were measured on day 0, 2 and 8. Intact GIP levels expectedly reflected normal fasting and postprandial values (range 6–55 pmol/l) and were correlated with the corresponding cortisol levels (r=0.59, P=0.004) on day 0. Mean cortisol levels were moderately suppressed on day 2 (60.4±12.7 vs. 43.7±10.2 μg/dl; P<0.01), but rose again on day 8 (49.8±10.4 μg/dl), which was accompanied by a significant suppression of postprandial GIP increases. However, lanreotide induced recurrent postprandial hyperglycaemia (up to 11.1 mmol/l) and failed to control clinical symptoms (hypertension, leg oedema). Unilateral adrenalectomy performed 6 months later did not influence pre- and postprandial intact GIP levels, but in turn normalised UFC during the first 4 weeks postoperatively (50.0–55.7 μg/24 hrs). After 6 weeks UFC increased again to supra-normal values, which necessitated continuation of treatment with A.

Conclusion: Although pathophysiologically justified, a single lanreotide administration in GIP-CS does not seem to effectively control hypercortisolism and it may worsen glucose metabolism. Short-term results of unilateral adrenalectomy are more convincing, but its curative effect may be transient.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.